1. LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. (23rd October 2018) Authors: Cappuzzo, F; McCleod, M; Hussein, M; Morabito, A; Rittmeyer, A; Conter, H J; Kopp, H-G; Daniel, D; McCune, S; Mekhail, T; Zer, A; Reinmuth, N; Sadiq, A; Archer, V; Ochi Lohmann, T; Wang, L; Kowanetz, M; Lin, W; Sandler, A; West, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA64nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study. (23rd October 2018) Authors: Spigel, D R; Jotte, R M; Ponce Aix, S; Gressot, L; Morgensztern, D; McCleod, M; Socinski, M A; Daniel, D; Juan-Vidal, O; Kim, E S; West, H J; Chen, T; Bhore, R; Ong, T J; Gridelli, C; Thomas, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Incidental Prostate Infections: Developing the Prostate Microbiome. (28th October 2020) Authors: Daniel, D; Zuretti, A Journal: American journal of clinical pathology Issue: Volume 154(2020)Supplement 1 Page Start: S138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗